Real-world Effectiveness of Casirivimab Plus Indevimab in a Dedicated Ambulatory Unit Created for Patients With Early COVID During a Massive Delta Variant Wave

Abstract Only few data are available on real-life effectiveness of neutralizing monoclonal antibodies to avoid hospitalization in high-risk patients with early COVID-19 not requiring supplemental oxygen. Our study analyzed the efficacy of casirivimab plus indevimab to prevent unfavorable outcomes in these patients. A dedicated Hospital Day Unit was created to treat during our 4th COVID wave 217 patients infected by the Delta variant. Mean age was 64 years, 94% had at least one comorbidity, and mean duration of symptoms was 2.9 days. Oxygen request, hospitalization, and mortality rates were respectively of 10, 6, and 2.8%. These results suggest efficacy of neutralizing antibodies infused in a dedicated ambulatory unit created for high-risk patients infected with a Delta variant at an early stage.